温抗体型自身免疫性溶血性贫血诊疗进展OA
Progress in diagnosis and treatment of warm antibody autoimmune hemolytic anemia
自身免疫性溶血性贫血(AIHA)是由自身抗体介导的红细胞过早破坏,60％～70％为温抗体型AIHA(wAIHA),由IgG介导的自身抗体所致.文章主要阐述wAIHA的诊疗进展,包括针对复发/难治wAIHA的各种新型疗法:靶向B细胞药物、靶向浆细胞药物、脾酪氨酸激酶抑制剂以及新生Fc受体抑制剂、补体抑制剂及CAR-T疗法等.这些进展为临床治疗提供了新思路和方案.
Autoimmune hemolytic anemia(AIHA)is characterized by destruction of red blood cells mediated by autoantibodies.Warm AIHA(wAIHA)accounts for 60％-70％of cases and is mainly caused by IgG-mediated autoantibodies.This article reviews the recent advances in the diagnosis and management of wAIHA,including several novel treatments in development for wAIHA:B-cell targeted agents,plasma cell targeted agents,spleen tyrosine kinase inhibitors,neonatal Fc receptor inhibitors,complement inhibitors,and CAR-T cell therapy.These advances provide new insights and strategies for clinical practice.
张雅文;何广胜
南京医科大学第一附属医院(江苏省人民医院)血液科 血液淋巴系统疾病细胞与基因治疗江苏省产业技术工程化中心,江苏南京 210029南京医科大学第一附属医院(江苏省人民医院)血液科 血液淋巴系统疾病细胞与基因治疗江苏省产业技术工程化中心,江苏南京 210029
医药卫生
贫血自身免疫性溶血温抗体诊断新药治疗
anemiaautoimmune hemolysiswarm antibodydiagnosisnovel agents
《中国实用内科杂志》 2026 (7)
551-557,7
国家自然科学基金青年基金(82400138,81900109)江苏省自然科学基金青年项目(BK20230734)
评论